Clinical trials and drug promotion : Selective reporting of study 329

  title={Clinical trials and drug promotion : Selective reporting of study 329},
  author={Jon N. Jureidini and Leemon B. McHenry and Peter R. Mansfield},
Selective reporting is prevalent in the medical literature, particularly in industry-sponsored research. In this paper, we expose selective reporting that is not evident without access to internal company documents. The published report of study 329 of paroxetine in adolescents sponsored by GlaxoSmithKline claims that “paroxetine is generally well tolerated and effective for major depression in adolescents”. By contrast, documents obtained during litigation reveal that study 329 was negative… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
34 Citations
25 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 34 extracted citations


Publications referenced by this paper.
Showing 1-10 of 25 references

Response to JAMA review

  • S. Laden
  • 10 Dec, 1999, PAR000757046-58; http://www…
  • 2007
Highly Influential
3 Excerpts

Adolescent depression: Efficacy of paroxetine

  • R. Berard, N. Ryan
  • Poster at European College of…
  • 2007
1 Excerpt


  • K. Wagner, B. Birmaher, G. Carlson, G. Clarke, G. Emslie
  • Geller et al., Safety of paroxetine and…
  • 2007

Paroxetine and imipramine in the treatment of adolescent depression (Abstract NR562:209)

  • M. B. Keller, N. D. Ryan, +4 authors E. B. Weller
  • Presentation to American Psychiatric Association…
  • 2007
1 Excerpt

Paroxetine in adolescent depression

  • C. Gagiono
  • Poster at World Congress of Psychiatry, Hamburg…
  • 2007
1 Excerpt

Seroxat/Paxil adolescent depression position piece on the Phase III clinical studies, October 1998, PAR003019178;

  • SmithKline Beecham
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…